ApoCell will support Pfizer’s Phase I cancer trial with patient selection as well as pharmacodynamic studies. The firm will use its TEP™ (target expression profile) technology along with immunohistochemistry to generate data to select volunteers most likely to benefit from the drug. It will also process patient samples to quantify the compound’s activity. This early-stage study will be conducted in three sites in the U.S. and abroad.
